Daniel J. Lippis, the Corporate Vice President for JAPAC at Edwards Lifesciences Corp (NYSE:EW), has disclosed recent stock ...

Wolfe Research adjusted its perspective on Edwards Lifesciences (NYSE:EW) shares, downgrading its rating from Peerperform to ...

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Capital Investment Advisors LLC lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.4% during the fourth quarter, according to its most recent disclosure with the ...

This was the stock's fourth consecutive day of losses.

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...

In a report released yesterday, Lee Hambright from Bernstein maintained a Hold rating on Edwards Lifesciences (EW – Research Report). The ...

Edwards Lifesciences Corp (EW) stock saw a decline, ending the day at $71.09 which represents a decrease of $-2.33 or -3.17% from the prior close of $73.42. The stock opened at $70.54 and touched a ...

On Monday, January 13, the U.S. Supreme Court issued an order list denying petitions for writ of certiorari in three cases ...

The US Supreme Court rejected a case asking the justices to interpret a patent-infringement safe-harbor provision in a ...